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ITZ-1 is a chondroprotective agent that inhibits inter-
leukin-1b–induced matrix metalloproteinase–13
(MMP-13) production and suppresses nitric oxide–
induced chondrocyte death. Here we describe its
mechanisms of action. Heat shock protein 90
(Hsp90) was identified as a specific ITZ-1–binding
protein. Almost all known Hsp90 inhibitors have
been reported to bind to the Hsp90 N-terminal ATP-
binding site and to simultaneously induce degrada-
tion and activation of its multiple client proteins.
However, within the Hsp90 client proteins, ITZ-1
strongly induces heat shock factor–1 (HSF1) activa-
tion and causes mild Raf-1 degradation, but scarcely
induces degradation of a broad range of Hsp90 client
proteins by binding to the Hsp90 C terminus. These
results may explain ITZ-1’s inhibition of MMP-13
production, its cytoprotective effect, and its lower
cytotoxicity. These results suggest that ITZ-1 is a
client-selective Hsp90 inhibitor.
INTRODUCTION
Osteoarthritis (OA) is a degenerative joint disease characterized
by slow but irreversible progressive destruction of articular
cartilage. The sustained production of interleukin (IL)–1 in the
affected joint may play a key role in OA pathogenesis (Aigner
et al., 2006; Ge et al., 2006). IL-1 induces up-regulation of matrix
metalloproteinases (MMPs) that degrade principal matrix macro-
molecules, such as proteoglycans and collagens, in cartilage.
Proteoglycans have a high turnover rate, whereas type II collagen
has a low turnover rate; thus, type II collagen degradation is a
committed step in OA progression. Within the approximately
20-member MMP-family, MMP-1, MMP-8, and MMP-13 are
interstitial collagenases that degrade type II collagen; in partic-
ular, MMP-13 may play a pivotal role in cartilage degradation
(Ge et al., 2006; Takaishi et al., 2008).
IL-1 has also been reported to induce death in chondrocytes,
which regulate cartilage metabolism, probably via nitric oxide
(NO) production (Yasuhara et al., 2005). Because the chondro-
cytes constitute the only cell type of the articular cartilage,
survival of the chondrocytes is essential for the maintenance of18 Chemistry & Biology 17, 18–27, January 29, 2010 ª2010 Elseviernormal articular cartilage (Presle et al., 1999; Ku¨hn et al., 2004).
Because there are no known therapeutic agents proven to
prevent erosion of articular cartilage or slow disease progres-
sion, agents that interfere with cartilage destruction would be
of considerable therapeutic value (Ku¨hn et al., 2004; Aigner
et al., 2006; Ge et al., 2006).
To develop therapeutic drugs for OA, we have searched for
chondroprotective agents and found N-{(1Z)-5,6-Dimethyl-
3-oxo-8-[(4,4,5,5,5,-pentafluoropentyl)thio]-2,3-dihydro-1H-imi-
dazo[5,1-c][1,4]thiazin-1-ylidene}-4methylbenzenesulfonamide,
ITZ-1 (Kimura et al., 2009), which suppresses IL-1b–induced
cartilage degradation in vitro and in vivo (Pettipher et al., 1986;
Cawston et al., 1995; Bottomley et al., 1997). ITZ-1 selectively
inhibits IL-1b–induced MMP-13 production with a half-maximal
inhibitory concentration (IC50) of 0.51 mM via inhibition of extra-
cellular signal–regulated protein kinase (ERK) activation (Vincenti
and Brinckerhoff, 2002; Ahmed et al., 2004, 2005), and
suppresses NO-induced death in human articular chondrocytes
(HACs) (Terauchi et al., 2003). Thus, ITZ-1 could be a promising
lead compound for a disease-modifying anti-OA drug program.
However, the precise mechanisms of action of ITZ-1 have been
poorly understood.
Here, we describe the molecular mechanisms of ITZ-1. We
identified heat shock protein 90 (Hsp90) (Whitesell and Lindquist,
2005; Sharp and Workman, 2006; Neckers, 2007) as a target
protein of ITZ-1 by use of drug-affinity chromatography (Harding
et al., 1989; Taunton et al., 1996; Shimizu et al., 2000; Sato et al.,
2007) and have further elucidated its downstream molecular
mechanisms. Hsp90 is involved in the folding, activation, and
assembly of several proteins, known as Hsp90 client proteins,
and the inhibition of Hsp90 function has been considered to
simultaneously induce degradation and activation of these
multiple client proteins (Whitesell and Lindquist, 2005; Sharp
and Workman, 2006; Neckers, 2007). However, several recent
reports have suggested the existence of small molecule inhibi-
tors of Hsp90 with client selective properties (Yu et al., 2005;
Salehi et al., 2006; Gallo, 2006; Ansar et al., 2007; Lu et al.,
2009). Interestingly, ITZ-1 strongly induced heat shock factor–1
(HSF1) activation and caused mild Raf-1 degradation without
affecting other Hsp90 client proteins by binding to the Hsp90 C
terminus (Whitesell and Lindquist, 2005). Considering the
definitive evidence that Hsp90 plays pivotal roles in multiorgan
physiology and pathology, the discovery we present here may
provide an approach to the development of therapeutic drugs
targeting Hsp90.Ltd All rights reserved
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Figure 1. Identification of Hsp90 as an ITZ-1-Binding Protein
(A) Chemical structure of ITZ-1.
(B) Chemical structures of ITZ-1 derivatives used for drug-affinity chromatography.
(C) Chemical structures of ITZ-1 derivatives used to estimate the potencies of derivatives shown in (B) on the matrix.
(D) Inhibitory activities of the ITZ-1 derivatives against IL-1b–induced MMP-13 production in HACs. Results shown are means ± SD (n = 3).
(E) Identification of Hsp90 from protein extracts as an ITZ-1–binding protein by drug-affinity chromatography. ITZ-2-, ITZ-3-, and ITZ-4-columns were used as
positive columns. As a control, a matrix on which no compound was immobilized was used (control-column). Lane 1, molecular weight (MW) marker; lane 2,
protein extract; lane 3, flow-through fraction; lanes 4 and 5, binding buffer wash fractions; lanes 6–10, 1 M NaCl-eluted fractions; and lane 11, glycine-HCl
buffer-eluted fraction. Arrows indicate the Hsp90 protein.
(F) Direct binding of His-hHsp90a to the ITZ-4-column. The ITZ-5-column was used as a negative control. Lane 1, MW marker; lane 2, His-hHsp90a; lane 3,
flow-through fraction; lanes 4–8, binding buffer wash fractions; and lanes 9–13, 6 M urea buffer-eluted fractions. Arrows indicate the His-hHsp90a protein.
See also Table S1.
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ITZ-1 a Client-Selective Hsp90 InhibitorRESULTS
Identification of Hsp90 as a Possible ITZ-1–Binding
Protein
The initial goal of the study was to identify the possible target
proteins of ITZ-1 (Figure 1A; see Table S1 available online) by use
of drug-affinity chromatography. A terminal carboxyl or amino
group was needed to couple small molecules to AF-amino or
AF-carboxy TOYOPEARL 650 matrix; however, ITZ-1 does not
possess these groups. Thus, two carboxyl derivatives, ITZ-2
and ITZ-3, and two amino derivatives, ITZ-4 and ITZ-5, of ITZ-1
were prepared for affinity chromatography (Figure 1B; Table S1).
ITZ-2 and ITZ-4 are structurally similar to ITZ-1. ITZ-3 and ITZ-5
were selected because previous studies have shown that intro-
duction of a trifluoromethyl group to the 4-position of benzene
ring in the (phenylsulfonyl)imino group retained activity, whereas
introduction of an acetylamino group to the same position re-
sulted in a decrease in activity. Because each compound was
immobilized to the matrix by coupling with a spacer arm at the
terminal carboxyl or amino group, we estimated the potency of
each compound on the matrix by using compounds coupled
with a long alkyl chain instead of a spacer arm. Potencies of
ITZ-2, ITZ-3, ITZ-4, and ITZ-5 on the matrix were estimatedChemistry & Biology 17,with ITZ-6, ITZ-7, ITZ-8, and ITZ-9, respectively (Figure 1C;
Table S1). ITZ-6, ITZ-7, and ITZ-8 inhibited IL-1b–induced
MMP-13 production and exhibited an IC50 of 3.2 mM, 2.0 mM,
and 4.0 mM, respectively, whereas ITZ-9, even at 10 mM, did not
show any detectable activity (Figure 1D). We hypothesized that
common binding proteins of matrix coupled with ITZ-2, ITZ-3,
and ITZ-4, but not ITZ-5, would also bind to ITZ-1. Thus, columns
of ITZ-2–, ITZ-3–, and ITZ-4–coupled matrixes (ITZ-2-column,
ITZ-3-column, and ITZ-4-column) were used as positive
columns, and an ITZ-5–coupled matrix column (ITZ-5-column)
was used as a negative column. We also utilized a column of
AF-amino TOYOPEARL 650 matrix on which no compound
was immobilized as another negative control column (control-
column).
There was a possibility that the binding affinity of ITZ-5 to the
target proteins was only 10 times less than that of ITZ-2, ITZ-3,
and ITZ-4 (Figure 1D), which could result in the binding of target
proteins to both positive and negative columns in some condi-
tion. Therefore, we used control-column instead of ITZ-5-column
for initial search. Chondrocyte protein extracts were applied to
the ITZ-2-, ITZ-3-, ITZ-4-, and control-column. After washing
the columns with binding buffer, bound proteins were eluted
with 1 M NaCl-containing buffer followed by glycine-HCl buffer.18–27, January 29, 2010 ª2010 Elsevier Ltd All rights reserved 19
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Figure 2. Direct Interaction between ITZ-1 and Hsp90
(A) Chemical structures of ITZ-1 derivatives.
(B) MMP-13 production inhibitory activities of ITZ-1 derivatives. Results shown
are means ± SD (n = 3).
(C) Specific binding of His-hHsp90a to ITZ-3–immobilized matrixes. ITZ-3–
immobilized matrix or control matrix was incubated with His-hHsp90a with
agitation, and then bound protein was analyzed by SDS-PAGE followed by
CBB staining.
(D) Displacement studies with ITZ-1 derivatives by the binding assay using
ITZ-3-immobilized matrixes. The binding reactions were performed as in (C)
in the presence of free compounds. See also Table S1and Figure S1.
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ITZ-1 a Client-Selective Hsp90 InhibitorBy analyzing each fraction, a common binding protein with a
molecular mass of 90 kDa (indicated by arrows) was identified
in the glycine-HCl buffer-eluted fractions of the three positive
columns (Figure 1E). This 90-kDa protein was not obtained
from the control-column, indicating that it was retained in these
positive columns by binding to the compound, but not to the
solid support. Amino acid sequence analysis revealed that the
90-kDa protein was Hsp90. The two closely related cytosolic iso-
forms of Hsp90 (Hsp90a and Hsp90b) were identified (Whitesell
and Lindquist, 2005).
To exclude the possibility that the interactions between the
ITZ-1 derivatives and Hsp90 are indirect or nonspecific, we
analyzed the binding of ITZ-1 derivatives to purified recombinant
Hsp90a (His-hHsp90a) using the drug-coupled columns. The
ITZ-4-column was used as a positive column, and the ITZ-5-
column was used as a negative column. His-hHsp90a was
diluted with binding buffer and then applied to the drug-coupled
columns. After washing the columns with binding buffer, bound
protein was eluted with the elution buffer containing 6 M urea.
Analysis of each fraction by SDS-PAGE followed by silver stain-
ing revealed that His-hHsp90awas retained in the positive ITZ-4-
column, but not in the negative ITZ-5-column, and was eluted
with elution buffer (Figure 1F). These results suggest that ITZ-1
derivatives interact directly with Hsp90a, and the rank order of
the derivatives in the inhibition of MMP-13 production might
agree well with that of the binding affinity for Hsp90.
Direct Interaction Between ITZ-1 and Hsp90a
Next, we investigated the direct interaction between ITZ-1 deriv-
atives and Hsp90a by two distinct binding assays. To obtain
further insights into the structure-activity relationship for ITZ-1
derivatives, we selected ITZ-1 and three other derivatives without
the terminal carboxyl/amino group or the long alkyl chain (ITZ-
10, ITZ-11, and ITZ-12; Figure 2A; Table S1). ITZ-1 was most
potent, followed by ITZ-10, ITZ-11, and ITZ-12, in the inhibition
of IL-1b–induced MMP-13 production in HACs (Figure 2B).
First, we analyzed the ITZ-1-Hsp90a interaction with the ITZ-
3–immobilized matrix. To test the functionality of the ITZ-3–im-
mobilized matrix, ITZ-3–immobilized matrix or control matrix
was incubated with His-hHsp90a with agitation, and then bound
protein was analyzed by SDS-PAGE followed by Coomassie bril-
liant blue R250 (CBB) staining. His-hHsp90awas recovered from
the ITZ-3–immobilized matrix, but not from the control matrix
(Figure 2C). This result shows that ITZ-3–immobilized matrix can
be used to measure the affinity of ligands that bind to the ITZ-3–
binding site of Hsp90a. Under these conditions, the binding
reactions were performed in the presence of free compounds.
Analysis of the bound protein to the ITZ-3–immobilized matrix re-
vealed that ITZ-1 was most potent, followed by ITZ-10, ITZ-11,
and ITZ-12, in the competitive inhibition of Hsp90a-ITZ-3 binding
(Figure 2D).
Next, we developed a scintillation proximity assay (SPA assay)
based on the detection of the radioligand [3H]-ITZ-1 binding
to a 6His-tagged Hsp90a protein (His2-hHsp90a), which was
captured by Ysi (2–5 mm) copper His-tag SPA beads (Graziani
et al., 1999). In this assay, [3H]-ITZ-1 binding to Hsp90a led to
the excitation of the scintillant contained in the SPA beads,
and the concomitant light emission was measured. Using 40
nM of [3H]-ITZ-1, specific interactions between His2-hHsp90a20 Chemistry & Biology 17, 18–27, January 29, 2010 ª2010 Elsevierand ITZ-1 were detected; however, when other 6His-tagged
proteins were used instead of His2-hHsp90a, [3H]-ITZ-1 binding
was undetectable (Figure S1A). These data indicate that ITZ-1
itself interacts specifically with Hsp90a.
In the SPA assay measuring the competitive inhibition of
[3H]-ITZ-1 binding to His2-hHsp90a, ITZ-1 was the most potent,
followed by ITZ-10, ITZ-11, and ITZ-12, and exhibited IC50 of
1.9 mM, 3.9 mM, 86 mM, and 100 mM, respectively (Figure S1B).
Note that the rank order of the derivatives in the inhibition of
MMP-13 production agrees well with the binding affinities for
Hsp90a (Figures 2B and D and Figure S1B). ITZ-1 might inhibit
MMP-13 production via binding to Hsp90. Interestingly, gelda-
namycin (GA), which binds to the Hsp90 N-terminal ATP-binding
site (Whitesell and Lindquist, 2005; Sharp and Workman, 2006;
Neckers, 2007), hardly inhibited the ITZ-1-Hsp90a interaction
at concentrations less than 100 mM (Figure S1B). ITZ-1 might
not bind to the N-terminal ATP-binding site of Hsp90.
ITZ-1 Inhibits IL-1b–Induced ERK Activation
via Raf-1 Degradation
We have reported that ITZ-1 selectively inhibited IL-1b–induced
extracellular signal–regulated protein kinase (ERK) activation
without affecting p38 kinase or c-Jun N-terminal kinase (JNK)
activation (Kimura et al., 2009). As an Hsp90 client protein,
Raf-1, which triggers ERK activation, is one IL-1b–signaling
intermediate (Vincenti and Brinckerhoff, 2002), and Raf-1 protein
levels are known to be decreased by Hsp90 inhibition (Stancato
et al., 1997; Sharp and Workman, 2006; Neckers, 2007). We
examined whether ITZ-1 could decrease Raf-1 protein levelsLtd All rights reserved
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Figure 3. Effects of ITZ-1 and ITZ-12 on the Raf-1 Protein Levels and
IL-1b–Induced ERK Activation in HACs
HACs were treated with ITZ-1 or ITZ-12 for 24 hr followed by stimulation with
IL-1b for 30 min. Raf-1 protein levels and total or phosphorylated protein levels
of ERK in equal amounts of whole-cell lysates were detected by western blot
analysis and quantitated by densitometry. b-actin was used as a control.
Chemistry & Biology
ITZ-1 a Client-Selective Hsp90 Inhibitorusing ITZ-12 with a lower Hsp90 binding affinity as a control
(Figure 2D; Figure S1B). HACs were pretreated with compounds
for 24 hr and then stimulated with 10 ng/ml of IL-1b for 30 min to
induce ERK activation. ITZ-1, but not ITZ-12, decreased Raf-1
protein levels and inhibited the IL-1b–induced ERK activation
at similar concentrations (Figure 3). ITZ-1, by binding to Hsp90,
might inhibit the MMP-13 production through an inhibition of
ERK activation via decreased Raf-1 protein levels.ITZ-1 Binds to the Hsp90 C Terminus Without Inhibiting
Hsp90 ATPase Activity
Hsp90 consists of three domains that have important functional
interactions: the N-terminal domain contains the ATP-binding
site and has ATPase activity, the middle domain interacts with
client proteins and cochaperons and activates the ATPase
activity, and the C-terminal domain is responsible for its inherent
dimerization. In eukaryotes, a flexible, highly charged region (CR)
connects the N-terminal domain to the middle domain (Whitesell
and Lindquist, 2005). GA, 17-allylaminogeldanamycin (17-AAG),
radicicol (RAD), and CCT018159 (CCT) bind to the N-terminal
ATP-binding site, whereas novobiocin (NOV) has been reported
to bind with poor affinity to a second ATP-binding site on the
Hsp90 C-terminal domain (Marcu et al., 2000a, 2000b; Whitesell
and Lindquist, 2005; Sharp and Workman, 2006; Neckers, 2007).A B C
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Figure 4. ITZ-1 Binds to the C-terminal Domain of Hsp90 Without Inhib
(A) Effects of ITZ-1 and various Hsp90 inhibitors on Hsp90a ATPase activity. A col
molybdate complex and subsequent reaction with malachite green, was used to m
(n = 3).
(B) Displacement studies with ITZ-1 and various Hsp90 inhibitors by the binding
(C) Schematic representation of the human Hsp90a (His-hHsp90a; Wt) and its d
region; M, middle domain; C, C-terminal domain. Specific binding of Wt, D1, D2
of ITZ-1 on the interaction between ITZ-3–immobilized matrix and these Hsp90 p
Chemistry & Biology 17,To obtain insights into the ITZ-1–binding site, we assessed
whether ITZ-1 could inhibit ATPase activity. A colorimetric assay
for inorganic phosphate, based on the formation of a phospho-
molybdate complex and subsequent reaction with malachite
green, was used to measure the ATPase activity of human
Hsp90a (Rowlands et al., 2004). The N-terminal ligands exhibited
potent inhibitory activities (IC50 of GA, 17-AAG, RAD, and CCT
were 3.1 mM, 4.6 mM, 4.1 mM, and 3.7 mM, respectively), whereas
neither ITZ-1 nor NOV showed detectable activities at concen-
trations <100 mM (Figure 4A). These data suggest that ITZ-1
does not bind to the N-terminal ATP-binding site.
In the competitive inhibition of Hsp90a-ITZ-3 binding, GA,
17-AAG, and RAD at 100 mM and NOV at 1000 mM did not exhibit
any activity, whereas CCT at 100 mM showed partial inhibition
(Figure 4B). These results suggest that ITZ-1 does not bind
to Hsp90 at the same site as GA, 17-AAG, RAD, and NOV do
in solution, or the binding affinity of ITZ-1 for Hsp90 is much
stronger compared to those compounds.
The ITZ-1–binding site on Hsp90 was further examined by
analyzing several deletion fragments for binding to the ITZ-3–im-
mobilized matrix (Whitesell and Lindquist, 2005). Interestingly,
removal of 77% of the N-terminal domain and CR between resi-
dues 48 and 290 (designated D1) or removal of CR and 70% of
the middle domain between residues 197 and 528 (designated
D2) from His-hHsp90a retained ITZ-3 binding, whereas removal
of the C-terminal domain between 645 and 732 (designated D3)
markedly impaired ITZ-3 binding (Figure 4C). The binding of D1
and D2 to the ITZ-3–immobilized matrix was also competitively
inhibited by ITZ-1, suggesting that the ITZ-1–binding domain
on Hsp90 is within its C-terminal domain.ITZ-1 Is Comparable to GA in the Induction of Hsp
Expression
Because the Hsp90-binding domain of ITZ-1 seemed to be
different from those of other Hsp90 inhibitors, including GA,
17-AAG, and RAD, we determined to investigate the Hsp90
inhibitory properties of ITZ-1. Hsp90 inhibitors have been
reported to induce Hsp expression by dissociating the HSF1/
Hsp90 complex (Zou et al., 1998; Sittler et al., 2001; Mimnaugh
et al., 2004; Shen et al., 2005). To test whether ITZ-1 could0 12.5  25  50   (mM)
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Figure 5. HSF1 Activation and Hsp70 and Hsp90 Induction by ITZ-1
(A) Up-regulation of Hsp70 and Hsp90 mRNA by ITZ-1 or GA. HACs were treated with ITZ-1 or GA in the presence or absence of IL-1b (10 ng/ml) for 24 hr.
Messenger RNA levels of Hsp70 and Hsp90 were measured by real-time quantitative PCR. Results shown are means ± SD (n = 3).
(B) Up-regulation of Hsp70 and Hsp90 protein by 48 hr treatment with ITZ-1 or GA. Protein levels of Hsp70 and Hsp90 were detected by western blot analysis.
b-actin was used as a control.
(C) Induction of Hsp70 mRNA expression by ITZ-1 derivatives or various Hsp90 inhibitors in the presence of IL-1b (10 ng/ml) costimulation. Results shown are
means ± SD (n = 3).
(D) ITZ-1 and GA, but not ITZ-12, disrupted the HSF1-Hsp90 complex in the cell lysates obtained from IL-1b–stimulated HAC. Coimmunoprecipitation using an
anti-Hsp90 antibody followed by western blot analysis of HSF1 (top) and Hsp90 (bottom) was performed. Coimmunoprecipitation was performed in the presence
or absence of 1 mM ITZ-1, ITZ-12, or GA (lanes 1–6) and various concentrations of ITZ-1 or GA (lanes 7–15). See also Figure S2.
Chemistry & Biology
ITZ-1 a Client-Selective Hsp90 Inhibitorinduce Hsp expression, HACs were stimulated with ITZ-1 or GA
in the presence or absence of IL-1b costimulation. Both ITZ-1
and GA increased mRNA and protein levels of Hsp70 and
Hsp90 in HACs in the presence of IL-1b costimulation (Figures
5A and 5B). It is well known that there are various approaches
to induce Hsp expression using pharmacological interventions.
Therefore, we investigated in detail whether ITZ-1 induced Hsp
expression by binding to Hsp90.
We first examined the structure-activity relationship in the
induction of Hsp70 expression for the ITZ-1 derivatives. With
IL-1b costimulation, ITZ-1 and ITZ-10 dramatically up-regulated
Hsp70 mRNA, whereas ITZ-11 and ITZ-12 showed little or no
Hsp70 up-regulation at concentrations <10 mM (Figure 5C).
This rank order was in good agreement with their order in the
binding affinity for Hsp90a (Figure 2D; Figure S1B). Thus, ITZ-1
may induce Hsp70 expression via binding to Hsp90. ITZ-1 was
more potent than known Hsp90 inhibitors in the induction of
Hsp70 expression; the concentrations of ITZ-1, GA, 17-AAG,
RAD, CCT, and NOV required to double the Hsp70 mRNA level
(the minimum effective concentration, MEC2.0) were 0.042 mM,
0.19 mM, 0.55 mM, >10 mM, 0.97 mM, and 240 mM, respectively
(Figure 5C). On the other hand, ITZ-1 was the least toxic to HACs
(Figure S2); the effective concentration 50 (EC50) of ITZ-1, GA,
17-AAG, RAD, CCT, and NOV were >10 mM, 0.32 mM, 1.2 mM,
13 mM, >10 mM, and 200 mM, respectively; thus, this potent
Hsp induction was not a byproduct of cytotoxicity.
The coimmunoprecipitation (IP) study conducted in the pres-
ence of free compounds in the lysates revealed that ITZ-1 at
1 mM, but not ITZ-12, drastically decreased the amount of HSF1
coprecipitated with Hsp90 (Figure 5D). The rank order was in22 Chemistry & Biology 17, 18–27, January 29, 2010 ª2010 Elseviergood agreement with their order of binding affinity for Hsp90a.
Moreover, the potency of ITZ-1 in the dissociation of HSF1/
Hsp90 complexes was equal to that of GA (Figure 5D). This result
agreed well with the results shown in Figures 5A and 5B. These
results suggest that ITZ-1 induced Hsp expression via binding
to Hsp90 and that the potency of ITZ-1 was at least equivalent
to that of GA.
ITZ-1 Is Over Three Orders of Magnitude Less Potent
in the Degradation of Several Hsp90 Client Proteins
than GA
Hsp90 inhibitors have been reported to induce degradation of
its multiple client proteins (Whitesell and Lindquist, 2005; Sharp
and Workman, 2006; Neckers, 2007). To further address the
Hsp90 inhibitory property of ITZ-1, HACs were treated with
ITZ-1 or known Hsp90 inhibitors for 24 hr, and then degrada-
tion of Hsp90 client proteins, such as Raf-1, glucocorticoid
receptor (GR), Akt, epidermal growth factor receptor (EGF-R),
and receptor interacting protein (RIP), was analyzed (Stancato
et al., 1997; Lewis et al., 2000; Bagatell et al., 2005; Zhang et al.,
2007a, 2007b). Interestingly, ITZ-1 was less potent by over three
orders of magnitude than was GA in the degradation of a majority
of these client proteins (Figure 6A). ITZ-1 did not induceR50%
degradation of client proteins except Raf-1 at 10 mM, whereas
GA simultaneously reduced these client proteins at concentra-
tions >0.01 mM. Moreover, ITZ-1 at 0.1 mM induced more than
a 40% decrease of Raf-1, whereas there were no other client
proteins that were decreased by more than 40% with ITZ-1 at
10 mM. Both ITZ-1 and GA required IL-1b costimulation to induce
Hsp expression (Figures 5A and 5B); thus, we investigated theLtd All rights reserved
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Figure 6. ITZ-1 Selectively Induces Raf-1 Protein Degradation
HACs were treated with ITZ-1 or GA for 24 hr in the absence (A) or presence (B) of IL-1b (10 ng/ml) costimulation. Protein levels of various Hsp90 client proteins in
equal amounts of whole-cell lysates were assessed by western blot analysis and quantitated by densitometry. b-actin was used as a control. Dotted lines indicate
the concentration of compound required to induce aR50% decrease of each client protein level. See also Figure S3.
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ITZ-1 a Client-Selective Hsp90 Inhibitorclient protein degradation by ITZ-1 or GA in the presence of IL-1b
costimulation. However, IL-1b costimulation did not affect their
client protein degradation properties (Figure 6B). Other Hsp90
inhibitors also simultaneously induced degradation of these
client proteins (Figure S3A). The R50% degradation of these
five client proteins by ITZ-1, GA, 17-AAG, RAD, CCT, and NOV
was seen at concentrations of >10 mM, 0.01 mM, 0.1 mM, 0.1 mM,
10 mM, and 1000 mM, respectively.
To determine whether ITZ-1 down-regulates Raf-1 at the
protein level, HACs were treated with ITZ-1 together with cyclo-
heximide (CHX), a protein synthesis inhibitor (Nomura et al.,
2005). Evaluation of cellular Raf-1 protein level by western blot
analysis revealed that preexisting Raf-1 protein was markedly
decreased by ITZ-1 and CHX. In contrast, when cells were
treated with CHX alone, Raf-1 protein decreased to only 44%
of the initial amount after 24 hr, indicating a protein half-life of
about 24 hr. These data demonstrate that down-regulation of
Raf-1 protein occurred at the protein level (Figure S3B).
Previous research has suggested a link between GA and
degradation of Hsp90 client proteins via the proteasome
pathway (Mimnaugh et al., 2004; Nomura et al., 2005). We exam-
ined whether proteasomal degradation mediates the loss of
Raf-1 in ITZ-1–treated HACs using the proteasome inhibitor
MG132. Pretreatment with MG132 resulted in a remarkable
suppression of ITZ-1–induced Raf-1 degradation in HACs (Fig-
ure S3C). This result suggests that Raf-1 was degraded by the
proteasome.
DISCUSSION
ITZ-1 is a chondroprotective agent that suppresses IL-1b–
induced cartilage degradation in vitro and in vivo. ITZ-1 also
inhibits IL-1b–induced MMP-13 production and suppresses
NO-induced chondrocyte death (Kimura et al., 2009). Here, we
show the successful identification of Hsp90 as a target protein
of ITZ-1. Drug-affinity chromatography has played an importantChemistry & Biology 17,role in the identification of drug-binding proteins (Harding et al.,
1989; Taunton et al., 1996). However, in many cases, nonspecific
binding of proteins to solid support or to the compound itself
has complicated identification of target proteins, and examina-
tion of the precise connection between the function of the
selected binding proteins and activity of the drugs was not done
sufficiently (Shimizu et al., 2000; Sato et al., 2007). To facilitate
drug target identification, we estimated the potency of each
compound on the matrix after coupling with a long alkyl chain,
instead of a spacer arm, at their terminal carboxyl or amino
group. We also adopted a system that can select activity-asso-
ciated structure-specific binding proteins of compounds using
three columns of active compounds immobilized matrixes.
These devices might confer our higher purification efficiency of
Hsp90 as the target protein of ITZ-1.
We have previously shown that ITZ-1 as well as an ERK-MAPK
pathway inhibitor (U0126), but not a p38 kinase inhibitor
(SB203580) or a JNK inhibitor (SP600125), selectively inhibited
IL-1b–induced MMP-13 production (Kimura et al., 2009). Here
we showed that the rank order of ITZ-1 derivatives in the inhibi-
tion of MMP-13 production agreed well with their binding affinity
for Hsp90a. Furthermore, ITZ-1, but not ITZ-12, decreased Raf-1
protein levels and inhibited the IL-1b–induced ERK activation.
Thus ITZ-1, by binding to Hsp90, might inhibit MMP-13 produc-
tion by suppressing IL-1b–induced ERK activation via decreased
Raf-1 protein levels.
The rank order of ITZ-1 derivatives affecting the dissociation of
HSF1/Hsp90 complex and up-regulation of Hsp70 expression
also agreed well with their binding affinity for Hsp90a. These
results suggest that ITZ-1 induced Hsp expression by binding
to Hsp90. The Hsp up-regulation might confer the chondropro-
tective effects of ITZ-1 in vitro and in vivo (Kimura et al., 2009)
because Hsp70 induction has been shown to prevent NO-
induced apoptosis in chondrocytes and to efficiently help in the
recovery from osteoarthritis (Terauchi et al., 2003; Ku¨hn et al.,
2004; Ge et al., 2006; Grossin et al., 2006).18–27, January 29, 2010 ª2010 Elsevier Ltd All rights reserved 23
Table 1. Hsp90 Inhibitory Properties of ITZ-1 and Several Known
Hsp90 Inhibitors
ITZ-1 GA 17-AAG RAD CCT NOV
Hsp70 mRNA induction,
MEC2.0 (mM)
0.042 0.19 0.55 >10 0.97 240
Raf-1 degradation, EC50 (mM) 1 0.01 0.1 0.1 10 1,000
Client protein
degradation, EC50 (mM)
>10 0.01 0.1 0.1 10 1,000
Cytotoxicity, EC50 (mM) >10 0.32 1.2 13 >10 200
ATPase inhibition, IC50 (mM) >100 3.1 4.6 4.1 3.7 >100
MEC2.0 for Hsp70 mRNA induction was determined as the concentration
of each compound to double the Hsp70 mRNA level. EC50 for Raf-1
degradation was determined as the concentration of each compound
required to induce a R50% decrease in Raf-1 protein levels. EC50 for
client protein degradation was determined as the concentration of each
compound required to induce aR50% decrease of the five client protein
levels.
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ITZ-1 a Client-Selective Hsp90 InhibitorSo far, Hsp90 inhibitors, especially those that bind at the N-
terminal domain, have been considered to simultaneously induce
degradation or activation of multiple Hsp90 client proteins
(Whitesell and Lindquist, 2005; Sharp and Workman, 2006;
Neckers, 2007). In fact, all known Hsp90 inhibitors used in this
study simultaneously reduced cellular protein levels of several
Hsp90 client proteins in HACs. However, the Hsp90 inhibitory
property of ITZ-1 was client protein selective, compared with
these other Hsp90 inhibitors. ITZ-1 strongly induced Hsps
expression and mildly caused Raf-1 degradation but scarcely
induced degradation of client proteins other than Raf-1. ITZ-1,
GA, 17-AAG, RAD, CCT, and NOV required >240, 0.053, 0.18,
>0.01, 10, and 4.2 times lower concentrations, respectively, for
Hsp70 expression, compared with client protein degradation
(Table 1). Because HACs were used for these studies, different
uptake and metabolism rates of ITZ-1 by cells in each assay
had a negligible effect on the experimental results.
This unique property of ITZ-1 might be due to its unique
Hsp90-binding site; almost all known Hsp90 inhibitors bind to
the N-terminal ATP-binding domain and inhibit the ATPase
activity (Rowlands et al., 2004; Whitesell and Lindquist, 2005;
Sharp and Workman, 2006; Neckers, 2007), whereas ITZ-1 binds
to Hsp90 at a site in the C-terminal domain without affecting
ATPase activity. Although NOV has been reported to bind to
the Hsp90 C-terminal domain, its binding affinity was too weak
to understand the contribution of this site to the regulation of
Hsp90 function (Marcu et al., 2000a, 2000b; Whitesell and Lind-
quist, 2005). ITZ-1 may be useful for better understanding the
function of the Hsp90 C-terminal domain. Recently, a NOV
analog A4, which could induce client protein degradation at
70-fold lower concentrations than NOV, has been reported to
up-regulate Hsp90 levels at concentrations 1,000–10,000 fold
lower than that required for client protein degradation (Yu et al.,
2005; Ansar et al., 2007; Lu et al., 2009). AEG3482, an antiapop-
totic compound that has been shown to bind Hsp90 at a site
different from GA, has also been reported to induce HSF-1–
dependent Hsp70 production without causing client protein
degradation (Salehi et al., 2006; Gallo, 2006). Therefore, it is con-
ceivable that ITZ-1, a C-terminal inhibitor, possesses a mecha-
nism of action distinct from that of GA and other N-terminal24 Chemistry & Biology 17, 18–27, January 29, 2010 ª2010 Elsevierinhibitors. Our results, as well as results with A4 and AEG3482,
suggest that the C-terminal domain is suitable for the develop-
ment of HSF-1–selective Hsp90 inhibitors.
Up-regulation of Hsps, especially that of Hsp70, has been
shown to be of great therapeutic potential for various diseases,
such as ischemic heart disease, diabetes, stroke, trauma, and
various neurodegenerative diseases (Auluck and Bonini, 2002;
Sittler et al., 2001; Shen et al., 2005; So¨ti et al., 2005). Several
reports have shown that GA, via Hsp70 induction, is effective
as a cytoprotective agent (Sittler et al., 2001; Auluck and Bonini,
2002; Shen et al., 2005). However, it is well known that GA is
toxic to cells probably as a result of nonspecific degradation of
a broad range of client proteins. ITZ-1 was at least 300 times
less toxic than GA for growing HAC, probably because of its
client selectivity (Table 1). ITZ-1 type Hsp90 inhibitors may be
beneficial as Hsp inducers with lower cytotoxicity.
Both ITZ-1 and GA required IL-1b costimulation to induce
Hsp expression in chondrocytes. To become transcriptionally
competent, HSF1 requires homotrimerization, translocation from
the cytoplasm to the nucleus, hyperphosphorylation, and acqui-
sition of DNA-binding activity (Zou et al., 1998). Both ITZ-1 and
GA dissociated HSF1/Hsp90 complexes in the cell lysate; there-
fore, IL-1b signal may affect the activation step of free HSF1.
Actually, IL-1b stimulation has been reported to involve trimer
formation of HSF1 in human embryonic lung fibroblast cells
(Sasaki et al., 2002).
In summary, our results suggest that ITZ-1 is a client selective
Hsp90 inhibitor that selectively induces robust HSF1 activation
and mild Raf-1 degradation. ITZ-1 type Hsp90 inhibitors are
promising as Hsp70 inducers, as well as disease-modifying
anti-OA drugs. It seems difficult to discover Hsp90 inhibitors
with such mechanisms of action by classical genetics because
Hsp90 null mutants are lethal in eukaryotes (Young et al.,
2001). Furthermore, ITZ-1 type Hsp90 inhibitors could not be
obtained by conventional assays such as the ATPase assay.
Thus, the two binding assays we used here are useful to identify
additional ITZ-1 type Hsp90 inhibitors. Our study demonstrates
that forward chemical genetics can result in the more efficient
identification of new drugs and new molecular targets (Lokey,
2003; Saghatelian and Cravatt, 2005; Spring, 2005; Kawasumi
and Nghiem, 2007).
SIGNIFICANCE
ITZ-1, a lead compound for an antiosteoarthritis (OA) drug
program, was previously found to have protective effects
against interleukin-1b (IL-1b)–induced cartilage degradation
in vitro and in vivo by both selective inhibition of IL-1b–
induced matrix metalloproteinase–13 (MMP-13) production
via inhibition of extracellular signal–regulated protein kinase
(ERK) activation and suppression of nitric oxide (NO)–
induced chondrocyte death. Here, we report the elucidation
of its precise mechanisms of action. Heat shock protein 90
(Hsp90) was identified as a specific ITZ-1–binding protein.
ITZ-1 induced degradation of an Hsp90 client protein, Raf-
1, which triggers IL-1b–induced ERK activation and up-regu-
lation of a cytoprotective heat shock protein 70 (Hsp70) by
dissociating heat shock factor 1 (HSF1)/Hsp90 complexes,
which may account for its cytoprotective effect as wellLtd All rights reserved
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ITZ-1 a Client-Selective Hsp90 Inhibitoras a selective inhibition of MMP-13 production. Almost all
known Hsp90 inhibitors, including geldanamycin (GA), have
been reported to bind to the N-terminal ATP-binding site
of Hsp90 and simultaneously induce degradation and activa-
tion of its multiple client proteins. However, ITZ-1 specifi-
cally bound to the C-terminal domain of Hsp90 without
affecting Hsp90s ATPase activity. Interestingly, ITZ-1
strongly induced HSF1 activation and caused mild Raf-1
degradation but scarcely induced degradation of a broad
range of Hsp90 client proteins besides Raf-1. These results
suggest that ITZ-1 is a client-selective Hsp90 inhibitor.
ITZ-1 type Hsp90 inhibitors are promising as Hsp70 inducers
for various diseases, as well as disease-modifying anti-OA
drugs. It seems difficult to discover Hsp90 inhibitors with
such a mechanism of action by classical genetics because
Hsp90 null mutants are lethal in eukaryotes. Furthermore,
an ITZ-1 type Hsp90 inhibitor could not be obtained by
conventional assays such as the ATPase assay. Our study
demonstrates that forward chemical genetics can result in
the efficient identification of new drugs and new molecular
targets.
EXPERIMENTAL PROCEDURES
Materials
GA, malachite green, polyvinyl alcohol, ammonium molybdate, CHX, and anti-
b-actin antibody (A-5441) were from Sigma. Anti-Raf-1 antibody (sc-133), anti-
GR antibody (sc-8992), anti-EGF-R antibody (sc-03), and protein A/G-agarose
(sc-2003) were from Santa Cruz Biotechnology. Phosphorylated and nonphos-
phorylated state specific antibodies for ERK p44/p42 (9100), anti-Akt antibody
(9270), and anti-rabbit IgG, HRP-linked antibody (7074) were from Cell
Signaling Technology. Anti-Hsp70 antibody (H53220), anti-Hsp90 antibody
(H38220), and anti-RIP antibody (551042) were from BD Bioscience. Anti-
HSF1 antibody (SPA-901) was from Assay Design. Peroxidase-labeled affinity
purified antibody to mouse IgG (g) (074-1802) was from KPL; 17-AAG, RAD,
and NOV were from Wako. CCT was from Tocris Bioscience. ATP was from
Roche. IL-1b was from R & D Systems. HACs and Chondrocyte Growth
Medium (CGM) were from Lonza Walkersville. A 1:1 (v/v) mixture of Dulbecco’s
modified Eagle’s MEM (DMEM) and Ham’s F-12 medium (DMEM/F-12) was
from Invitrogen. Detailed methods for the syntheses of ITZ-1 derivatives are
described in Supplemental Information.
Assay for MMP Production
IL-1b–induced production of MMPs by HACs was measured as described
elsewhere (Kimura et al., 2009).
Drug-Affinity Chromatography
Two milliliters of 100 mM imidazo[5,1-c][1,4]thiazine derivatives dissolved in
75–95% DMF and 20 mg of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide
hydrochloride (EDC) were coupled to 1 ml of AF-Amino TOYOPEARL 650M
(Tosoh) or AF-Carboxy TOYOPEARL 650M (Tosoh), according to the manufac-
turer’s instructions.
HACs were homogenized in four volumes of binding buffer (10 mM Tris-HCl
[pH 7.5], 20% glycerol, 1 mM EDTA, 100 mM NaCl, 0.5 mM p-APMSF, and
1 mM DTT) with a teflon homogenizer. The homogenate was spun at
100,000 3 g for 60 min at 4C, and then the supernatant was recovered and
applied to the columns of drug-coupled matrixes. Columns were washed twice
with five volumes of binding buffer, and then binding proteins were eluted with
five volumes of elution buffer (10 mM Tris-HCl [pH 7.5], 20% glycerol, 1 mM
EDTA, 1 M NaCl, 0.5 mM p-APMSF, and 1 mM DTT) by collecting 5 fractions
equal to column volume, and with three volumes of glycine-HCl buffer (0.1 M
glycine-HCl [pH 2.7]).
His-hHsp90a was diluted to 50 mg/ml with binding buffer (10 mM Tris-HCl
[pH 7.5], 20% glycerol, 1 mM EDTA, 500 mM NaCl, and 1 mM DTT) and appliedChemistry & Biology 17,to the columns. After a wash with five volumes of binding buffer, binding
proteins were eluted with five volumes of elution buffer (10 mM Tris-HCl
[pH 7.5], 20% glycerol, 1 mM EDTA, 500 mM NaCl, and 6 M Urea). The eluted
proteins were analyzed by SDS-PAGE followed by silver staining.
Protein Identification by LC-MS/MS
The eluted proteins were subjected to SDS-PAGE, and then the gels were
stained with CBB. Protein spots were excised from the gel and subjected to
in-gel digestion followed by LC-MS/MS sequence analysis at APRO Life
Science Institute.
Expression and Purification of Recombinant Proteins
Expression and purification of recombinant proteins were accomplished by
the pET expression system (Merck) with His Bind Resin according to the
manufacturer’s instructions. Detailed methods are described in the Supple-
mental Experimental Procedures.
In Vitro Binding Assay with ITZ-3–Immobilized Matrix
One microgram of His-hHsp90a or deletion mutants was incubated with
sample in 200 ml of binding buffer (10 mM Tris-HCl [pH 7.5], 20% glycerol,
1 mM EDTA, 500 mM NaCl, and 1 mM DTT) at room temperature for 30 min.
After addition of 5 ml of ITZ-3–immobilized matrix or control matrix, the
mixtures were further incubated for 40 min with agitation. The matrixes were
washed five times with 200 ml of binding buffer and then heated for 5 min at
95C in SDS-PAGE sample buffer. The samples were subjected to SDS-
PAGE followed by CBB staining.
Evaluation of MAPK Activation and Hsp90 Client Protein
Degradation
ERK activation was evaluated as described elsewhere (Kimura et al., 2009). To
evaluate client protein degradation, HACs pr-cultured in CGM at a density of
43 104 cells/ml in 6-well plates for 1 day were further cultured in DMEM/F-12
supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin, and 20 mg/ml
gentamicin at 37C in 5% CO2/95% humidified air for 1 day, and then treated
with samples for 24 hr. HACs were lysed with lysis buffer (Kimura et al., 2009)
and then subjected to western blot analysis.
Western Blot Analysis
Samples were subjected to SDS-PAGE, transferred onto nitrocellulose filters
(Hybond-ECL; GE Healthcare), and immunoblotted with the primary antibodies
followed by horseradish peroxidase–conjugated secondary antibodies. The
immune complexes were visualized with an enhanced chemiluminescence
system (ECL Detection Kit; GE Healthcare) and Hyperfilm ECL (GE Healthcare),
according to the manufacturer’s instructions. Protein levels were calculated
from densitometrical analysis by GS-800 Calibrated Densitometer (Bio-Rad).
ATPase Activity Assay
The ATPase activity assay was performed as described elsewhere, using
human Hsp90a (ATGen) (Rowlands et al., 2004).
Evaluation of the Induction of Hsp Expression
HACs maintained in CGM were suspended in DMEM/F-12 supplemented with
50 U/ml penicillin and 50 mg/ml streptomycin at a density of 5.53 104 cells/ml
and were cultured in 96-well or 12-well plates at 37C in 5% CO2/95% humid-
ified air for 1 day. After medium exchange, HACs were treated with samples
and 10 ng/ml of IL-1b for 24 or 48 hr. Real-time quantitative PCR was per-
formed as described elsewhere (Kimura et al., 2009). Primers used for Hsp70
analysis were Hsp70-F (50-CGAGAGGGTGTCAGCCAAGA-30) and Hsp70-R
(50-AGCCACGAGATGACCTCTTGAC-30). Primers used for Hsp90 analysis
were Hsp90-F (50-TTGGTCCTGTGCGGTCACT-30) and Hsp90-R (50-CCATC
GGTTGGTCTTGGG-30). For western blot analysis, HACs were washed with
PBS and then lysed with lysis buffer (Kimura et al., 2009).
Immunoprecipitation
HACs were cultured in the presence 10 ng/ml of IL-1b for 24 hr, were washed
with PBS, were lysed with RIPA buffer (50 mM Tris-HCl [pH 8.0], 150 mM NaCl,
1% NP-40, 0.1% SDS, 0.5% deoxycholic acid, 1 mM sodium orthovanadate V,
and 1 mM microcystin-LR) with proteinase inhibitors (Complete; Boeringer18–27, January 29, 2010 ª2010 Elsevier Ltd All rights reserved 25
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ITZ-1 a Client-Selective Hsp90 InhibitorMannheim), and were centrifuged at 16,0003 g for 10 min, and then superna-
tant (lysates) was recovered. Next, 600 ml of lysates (2 mg/ml) were preincu-
bated with samples for 30 min and then were incubated with 30 mg of anti-
Hsp90 antibody (SPA-840; Assay Design) or control IgG (I4131; Sigma) for
30 min. Subsequently, the lysates were incubated with a 50-ml slurry of protein
A/G-agarose with rotation for 3 hr at 4C. The immunoprecipitates were
collected by centrifugation, washed seven times with RIPA buffer, and then
subjected to SDS-PAGE followed by western blot analysis using anti-HSF1
or anti-Hsp90 antibodies.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
1016/j.chembiol.2009.12.012.
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